181 related articles for article (PubMed ID: 33445205)
21. Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use.
Lamb YN
Clin Drug Investig; 2019 Nov; 39(11):1141-1147. PubMed ID: 31571127
[TBL] [Abstract][Full Text] [Related]
22. Botulinum toxin A for axillary hyperhidrosis (excessive sweating).
Heckmann M; Ceballos-Baumann AO; Plewig G;
N Engl J Med; 2001 Feb; 344(7):488-93. PubMed ID: 11172190
[TBL] [Abstract][Full Text] [Related]
23. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
Yokozeki H; Fujimoto T; Abe Y; Igarashi M; Ishikoh A; Omi T; Kanda H; Kitahara H; Kinoshita M; Nakasu I; Hattori N; Horiuchi Y; Maruyama R; Mizutani H; Murakami Y; Watanabe C; Kume A; Hanafusa T; Hamaguchi M; Yoshioka A; Egami Y; Matsuo K; Matsuda T; Akamatsu M; Yorozuya T; Takayama S
J Dermatol; 2021 Mar; 48(3):279-288. PubMed ID: 33410265
[TBL] [Abstract][Full Text] [Related]
24. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY;
J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
[TBL] [Abstract][Full Text] [Related]
25. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
Naumann M; Lowe NJ; Kumar CR; Hamm H;
Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503
[TBL] [Abstract][Full Text] [Related]
26. Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study.
Artzi O; Loizides C; Zur E; Sprecher E
Acta Derm Venereol; 2017 Oct; 97(9):1120-1124. PubMed ID: 28654131
[TBL] [Abstract][Full Text] [Related]
27. Two-week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis.
Fujimoto T; Okatsu H; Miyama H
J Dermatol; 2022 Jun; 49(6):594-599. PubMed ID: 35394087
[TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial.
Naumann M; Lowe NJ
BMJ; 2001 Sep; 323(7313):596-9. PubMed ID: 11557704
[TBL] [Abstract][Full Text] [Related]
29. A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis.
Glaser DA; Pariser DM; Hebert AA; Landells I; Somogyi C; Weng E; Brin MF; Beddingfield F
Pediatr Dermatol; 2015; 32(5):609-17. PubMed ID: 26059781
[TBL] [Abstract][Full Text] [Related]
30. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial.
Naumann MK; Hamm H; Lowe NJ;
Br J Dermatol; 2002 Dec; 147(6):1218-26. PubMed ID: 12452874
[TBL] [Abstract][Full Text] [Related]
31. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J
Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543
[TBL] [Abstract][Full Text] [Related]
32. Open-Label Cohort Study to Evaluate Efficacy and Safety of Application of Glycopyrronium Cloth, 2.4% for Palmar Hyperhidrosis.
Pariser D; Rivera E; Benedict D
J Drugs Dermatol; 2022 May; 21(5):488-495. PubMed ID: 35533035
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of iontophoresis with glycopyrronium bromide for treatment of primary palmar hyperhidrosis.
Chia HY; Tan AS; Chong WS; Tey HL
J Eur Acad Dermatol Venereol; 2012 Sep; 26(9):1167-70. PubMed ID: 21812834
[TBL] [Abstract][Full Text] [Related]
34. Radiofrequency Thermotherapy for Treating Axillary Hyperhidrosis.
Schick CH; Grallath T; Schick KS; Hashmonai M
Dermatol Surg; 2016 May; 42(5):624-30. PubMed ID: 27110892
[TBL] [Abstract][Full Text] [Related]
35. A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study.
Fujimoto T; Terahara T; Okawa K; Inakura H; Hirayama Y; Yokozeki H
J Am Acad Dermatol; 2023 Jul; 89(1):62-69. PubMed ID: 36990320
[TBL] [Abstract][Full Text] [Related]
36. Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis.
Nwannunu CE; Limmer AL; Coleman K; Shah R; Patel RR; Mui UN; Tyring SK
Skin Therapy Lett; 2019 Mar; 24(2):1-3. PubMed ID: 30970203
[TBL] [Abstract][Full Text] [Related]
37. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study.
Heckmann M; Plewig G;
Arch Dermatol; 2005 Oct; 141(10):1255-9. PubMed ID: 16230563
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of a new aluminium salt thermophobic foam in the treatment of axillary and palmar primary hyperhidrosis: a pilot exploratory trial.
Innocenzi D; Lupi F; Bruni F; Frasca M; Panetta C; Milani M
Curr Med Res Opin; 2005 Dec; 21(12):1949-53. PubMed ID: 16368045
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum chloride for the treatment of axillary hyperhidrosis: A randomized controlled trial.
Thianboonsong T; Kanokrungsee S; Paichitrojjana A; Udompataikul M; Kamanamool N; Rojhirunsakool S
Dermatol Ther; 2020 Nov; 33(6):e14354. PubMed ID: 32990370
[TBL] [Abstract][Full Text] [Related]
40. Pressure-and dose-controlled, needle-free, transcutaneous pneumatic injection of botulinum neurotoxin-A for the treatment of primary axillary and palmoplantar hyperhidrosis.
Kim HM; Lee MJ; Lee MH; Lee H
Skin Res Technol; 2020 Jul; 26(4):577-583. PubMed ID: 31922304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
